JPMorgan Chase & Co. Increases Stock Holdings in HilleVax, Inc. (NASDAQ:HLVX)

JPMorgan Chase & Co. grew its holdings in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 1,376.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 207,151 shares of the company's stock after acquiring an additional 193,124 shares during the quarter. JPMorgan Chase & Co. owned about 0.42% of HilleVax worth $429,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new stake in shares of HilleVax during the fourth quarter worth about $26,000. Ieq Capital LLC grew its position in HilleVax by 71.1% during the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock valued at $47,000 after purchasing an additional 9,344 shares during the last quarter. SG Americas Securities LLC raised its holdings in HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock worth $38,000 after acquiring an additional 6,916 shares during the last quarter. Barclays PLC increased its holdings in HilleVax by 255.6% in the 3rd quarter. Barclays PLC now owns 42,033 shares of the company's stock worth $74,000 after buying an additional 30,213 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of HilleVax by 81.7% during the third quarter. Jane Street Group LLC now owns 79,039 shares of the company's stock valued at $139,000 after purchasing an additional 35,546 shares during the last quarter. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Price Performance

HLVX stock traded down $0.03 during trading on Wednesday, hitting $1.85. The stock had a trading volume of 205,659 shares, compared to its average volume of 448,676. The stock has a market capitalization of $92.76 million, a P/E ratio of -0.60 and a beta of 0.78. HilleVax, Inc. has a twelve month low of $1.34 and a twelve month high of $16.31. The company's 50-day moving average price is $1.70 and its two-hundred day moving average price is $1.84.

HilleVax (NASDAQ:HLVX - Get Free Report) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). As a group, sell-side analysts expect that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a research note on Monday, March 31st. Six research analysts have rated the stock with a hold rating, Based on data from MarketBeat, HilleVax has a consensus rating of "Hold" and an average target price of $3.00.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.